Unitaid Warns of 'Pilotitis'… Prices Cut by Up to 65%
Remedi and AIDOT Expand Field Applications in the Philippines and Mongolia
Acryl Proposes Sustainable Operations Based on Local Infrastructure and Data Sovereignty
(From left) Janet Ginnard, Director of Strategy at Unitaid; Kim Young-gee, Advisor to Remedi; Jeong Jae-hoon, CEO of AIDOT; and Park Whee-jin, CEO of Acryl introduce strategies for national adoption of medical AI along with overseas application and operation cases at the KHIDI-Unitaid joint forum held at COEX Magok in Seoul on the 22nd. Photo = Reporter Min Jun-young
Evaluation criteria for medical artificial intelligence (AI) are expanding beyond technological performance to whether solutions can enter national healthcare systems. Experts diagnose that for AI, which has confirmed its potential in pilot projects, to spread on a national scale, procurement, financing, clinical connection, and local operational structures must be established together. Domestic medical AI companies also presented overseas application cases, such as tuberculosis screening in the Philippines and national cervical cancer screening in Mongolia.
The Korea Health Industry Development Institute (KHIDI) and Unitaid held a joint forum on the 22nd at COEX Magok in Seoul, sharing approach strategies for national adoption of medical AI and localization/operation plans tailored to resource-constrained environments.
.
.
.
AIDOT Expands Cervical Cancer AI via Government Tenders and Local Data
Jeong Jae-hoon, CEO of AIDOT, introduces overseas application cases of the on-device cervical cancer screening AI 'Cerviray AI' at the KHIDI-Unitaid joint forum on the 22nd. Photo = Reporter Min Jun-young
Jeong Jae-hoon, CEO of AIDOT, introduced 'Cerviray AI,' an on-device AI that supports cervical cancer screening in areas lacking specialized personnel and testing infrastructure. Cerviray AI analyzes visual inspection with acetic acid (VIA) images to present a 4-stage grade within 5 seconds, operating without an internet connection or external server.
CEO Jeong explained, "VIA allows results to be checked quickly at a low cost, but interpretation can vary depending on the subjective judgment of the examiner. By complementing this with AI, we support expert-level readings and enabled its use even in environments without internet or servers."
In Mongolia, AIDOT collaborated with local gynecologists to win a government tender and subsequently introduced Cerviray AI into the national screening campaign. The number of AI screenings has exceeded 55,000 cases, and related data is stored on local servers within Mongolia.
CEO Jeong said, "In Mongolia, mobile vehicles travel to remote regions such as the Gobi Desert to perform screenings. We operate in a way that safeguards data sovereignty by keeping data locally."
In Brazil, approximately 30,000 screenings were conducted in connection with hospital ships along the Amazon River. In Bolivia, following registration with local regulatory authorities, more than 100 units of equipment have been operated to perform over 6,880 AI screenings, and screening campaigns are also being conducted with the Bolivian National Cancer Center.
Cerviray AI is currently used in over 292 hospitals in South Korea, and cumulative screening cases including Korea and Mongolia have exceeded 220,000. It has received regulatory approval in 9 countries and has entered 14 countries including clinical trials and partnerships. In Indonesia, registration and prospective clinical trials are underway, and the company is preparing to expand operations into Mexico, Chile, Costa Rica, and other regions.
CEO Jeong stated, "A woman's opportunity to receive cervical cancer screening should not depend on the region where she was born," adding, "Our goal is to increase screening accessibility through AI that can be used even in regions lacking connectivity networks and testing infrastructure."
Medipana News / 2026-10-23 / Reporter Min Jun-young
